

Special Issue

Immune Response and Antigen-Specific Personalized Therapeutics in Multiple Sclerosis—the Upcoming Era of Precision Medicine

Message from the Guest Editors

Multiple sclerosis (MS) is an autoimmune disorder characterized by T cell-mediated demyelination and neurodegeneration of the central nervous system (CNS), whose exact etiology remains unclear. The autoimmune view of MS is strongly supported by the use of the animal *experimental autoimmune encephalomyelitis (EAE)* model, which displays some of the key MS characteristics. During the effector phase, CD4+ T cells that recognize antigen proliferate, cross the *blood–brain barrier (BBB)* and subsequently activate macrophages and *microglia* that cause demyelination, oligodendrocyte death, and axon degeneration. As the disease progresses, remyelination and regeneration of oligodendrocyte become inefficient and ultimately fail, resulting in disease progression. This Special Issue aims at gathering articles *on immune response toward personalized therapeutics in MS*, through the contribution of MS specialists around the world, taking into account the progress in the field in the last two decades.

Guest Editors

Dr. Maria Anagnostouli

1. Immunogenetics Laboratory, 1st Department of Neurology, Medical School of National and Kapodistrian University of Athens, Aeginition Hospital, Vas. Sophias, 74, 115 27 Athens, Greece

2. Multiple Sclerosis and Demyelinating Diseases Unit, Center of Expertise for Rare Demyelinating and Autoinflammatory Diseases of CNS, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, NKUA, Aeginition University Hospital, Vas. Sofias 72-74, 115 28 Athens, Greece

Prof. Dr. George P. Chrousos

University Research Institute of Maternal and Child Health and Precision Medicine, Medical School, "Aghia Sophia" Children's Hospital, National and Kapodistrian University of Athens, 15772 Athens, Greece

Deadline for manuscript submissions

closed (20 June 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/64847

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).